217 related articles for article (PubMed ID: 28159515)
1. Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease.
Date AA; Rais R; Babu T; Ortiz J; Kanvinde P; Thomas AG; Zimmermann SC; Gadiano AJ; Halpert G; Slusher BS; Ensign LM
J Control Release; 2017 Oct; 263():132-138. PubMed ID: 28159515
[TBL] [Abstract][Full Text] [Related]
2.
Rais R; Jiang W; Zhai H; Wozniak KM; Stathis M; Hollinger KR; Thomas AG; Rojas C; Vornov JJ; Marohn M; Li X; Slusher BS
JCI Insight; 2016 Aug; 1(12):. PubMed ID: 27536732
[TBL] [Abstract][Full Text] [Related]
3. Glutamate carboxypeptidase II (GCPII) inhibitor 2-PMPA reduces rewarding effects of the synthetic cathinone MDPV in rats: a role for N-acetylaspartylglutamate (NAAG).
Hicks C; Gregg RA; Nayak SU; Cannella LA; Schena GJ; Tallarida CS; Reitz AB; Smith GR; Rawls SM
Psychopharmacology (Berl); 2017 Jun; 234(11):1671-1681. PubMed ID: 28251297
[TBL] [Abstract][Full Text] [Related]
4. Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA).
Rais R; Rojas C; Wozniak K; Wu Y; Zhao M; Tsukamoto T; Rudek MA; Slusher BS
J Pharm Biomed Anal; 2014 Jan; 88():162-9. PubMed ID: 24055700
[TBL] [Abstract][Full Text] [Related]
5. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease.
Date AA; Halpert G; Babu T; Ortiz J; Kanvinde P; Dimitrion P; Narayan J; Zierden H; Betageri K; Musmanno O; Wiegand H; Huang X; Gumber S; Hanes J; Ensign LM
Biomaterials; 2018 Dec; 185():97-105. PubMed ID: 30236840
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of treatment with transglutaminase inhibitor cystamine on the severity of inflammation in a rat model of inflammatory bowel disease.
Elli L; Ciulla MM; Busca G; Roncoroni L; Maioli C; Ferrero S; Bardella MT; Bonura A; Paliotti R; Terrani C; Braidotti P
Lab Invest; 2011 Mar; 91(3):452-61. PubMed ID: 21042292
[TBL] [Abstract][Full Text] [Related]
7. A gut-restricted glutamate carboxypeptidase II inhibitor reduces monocytic inflammation and improves preclinical colitis.
Peters DE; Norris LD; Tenora L; Šnajdr I; Ponti AK; Zhu X; Sakamoto S; Veeravalli V; Pradhan M; Alt J; Thomas AG; Majer P; Rais R; McDonald C; Slusher BS
Sci Transl Med; 2023 Aug; 15(708):eabn7491. PubMed ID: 37556558
[TBL] [Abstract][Full Text] [Related]
8. Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration.
Rais R; Wozniak K; Wu Y; Niwa M; Stathis M; Alt J; Giroux M; Sawa A; Rojas C; Slusher BS
PLoS One; 2015; 10(7):e0131861. PubMed ID: 26151906
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent inhibition of GCPII to prevent and treat cognitive impairment in the EAE model of multiple sclerosis.
Hollinger KR; Alt J; Riehm AM; Slusher BS; Kaplin AI
Brain Res; 2016 Mar; 1635():105-12. PubMed ID: 26826008
[TBL] [Abstract][Full Text] [Related]
10. Astragaloside IV ameliorates 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis implicating regulation of energy metabolism.
Jiang XG; Sun K; Liu YY; Yan L; Wang MX; Fan JY; Mu HN; Li C; Chen YY; Wang CS; Han JY
Sci Rep; 2017 Feb; 7():41832. PubMed ID: 28150820
[TBL] [Abstract][Full Text] [Related]
11. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
12. Glutamate carboxypeptidase II (GCPII) inhibitor displays anti-glutamate and anti-cocaine effects in an invertebrate assay.
Tallarida C; Song K; Raffa RB; Rawls SM
Amino Acids; 2012 Jun; 42(6):2521-4. PubMed ID: 21850438
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Brain Delivery of 2-(Phosphonomethyl)pentanedioic Acid Following Intranasal Administration of Its γ-Substituted Ester Prodrugs.
Nedelcovych M; Dash RP; Tenora L; Zimmermann SC; Gadiano AJ; Garrett C; Alt J; Hollinger KR; Pommier E; Jančařík A; Rojas C; Thomas AG; Wu Y; Wozniak K; Majer P; Slusher BS; Rais R
Mol Pharm; 2017 Oct; 14(10):3248-3257. PubMed ID: 28763226
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of tranilast on experimental colitis in rats.
Seto Y; Kato K; Tsukada R; Suzuki H; Kaneko Y; Kojo Y; Sato H; Onoue S
Biomed Pharmacother; 2017 Jun; 90():842-849. PubMed ID: 28437888
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Oral Bioavailability of 2-(Phosphonomethyl)-pentanedioic Acid (2-PMPA) from its (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-Based Prodrugs.
Dash RP; Tichý T; Veeravalli V; Lam J; Alt J; Wu Y; Tenora L; Majer P; Slusher BS; Rais R
Mol Pharm; 2019 Oct; 16(10):4292-4301. PubMed ID: 31503493
[TBL] [Abstract][Full Text] [Related]
16. [Effects of Pim-1 inhibitor on mouse model of inflammatory bowel disease induced by TNBS].
Ou R; Shen Y; Zeng Y; Zou L; Jiang N; Xu M
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 May; 43(5):481-489. PubMed ID: 29886462
[TBL] [Abstract][Full Text] [Related]
17. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration.
Nagel J; Belozertseva I; Greco S; Kashkin V; Malyshkin A; Jirgensons A; Shekunova E; Eilbacher B; Bespalov A; Danysz W
Neuropharmacology; 2006 Dec; 51(7-8):1163-71. PubMed ID: 16926034
[TBL] [Abstract][Full Text] [Related]
18. Blocking glutamate carboxypeptidase II inhibits glutamate excitotoxicity and regulates immune responses in experimental autoimmune encephalomyelitis.
Ha D; Bing SJ; Ahn G; Kim J; Cho J; Kim A; Herath KH; Yu HS; Jo SA; Cho IH; Jee Y
FEBS J; 2016 Sep; 283(18):3438-56. PubMed ID: 27444540
[TBL] [Abstract][Full Text] [Related]
19. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease.
Zhang S; Ermann J; Succi MD; Zhou A; Hamilton MJ; Cao B; Korzenik JR; Glickman JN; Vemula PK; Glimcher LH; Traverso G; Langer R; Karp JM
Sci Transl Med; 2015 Aug; 7(300):300ra128. PubMed ID: 26268315
[TBL] [Abstract][Full Text] [Related]
20. Effect of recombinant Trichinella spiralis cysteine proteinase inhibitor on TNBS-induced experimental inflammatory bowel disease in mice.
Xu J; Liu M; Yu P; Wu L; Lu Y
Int Immunopharmacol; 2019 Jan; 66():28-40. PubMed ID: 30419451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
